Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762 INTASYL compound which reduces the expression of cell death Protein 1 (PD-1) a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4 a protein which controls gene expression in both T cells and tumor cells effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough Massachusetts.